tacrolimus

ApprovedCompleted
3 views this week 0 watching Active
Interest: 43/100
43
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
Phase 3
5
Approved
Indication / Disease

Moderate/Severe Atopic Dermatitis

Conditions

Moderate/Severe Atopic Dermatitis

Trial Timeline

Sep 1, 2012 → Nov 1, 2013

About tacrolimus

tacrolimus is a approved stage product being developed by Astellas Pharma for Moderate/Severe Atopic Dermatitis. The current trial status is completed. This product is registered under clinical trial identifier NCT01745159. Target conditions include Moderate/Severe Atopic Dermatitis.

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (20)

NCT IDPhaseStatus
NCT00189761Phase 2Completed
NCT00293930Phase 3Completed
NCT00189787Phase 2Completed
NCT00189722Phase 2Completed
NCT03465969ApprovedCompleted
NCT02555787Pre-clinicalCompleted
NCT02147938Pre-clinicalCompleted
NCT02143479Pre-clinicalCompleted
NCT02159651Pre-clinicalCompleted
NCT02057484Pre-clinicalCompleted
NCT02377609Pre-clinicalTerminated
NCT01745159ApprovedCompleted
NCT01511003ApprovedCompleted
NCT01316133ApprovedTerminated
NCT01410162ApprovedCompleted
NCT02963103ApprovedTerminated
NCT01224041ApprovedCompleted
NCT01224418ApprovedCompleted
NCT00504348Phase 2/3Completed
NCT01410747Pre-clinicalCompleted